Serina Therapeutics Announces POZ Polymer Technology License Agreement With Pfizer
Portfolio Pulse from Benzinga Newsdesk
Serina Therapeutics has entered into a non-exclusive License Agreement with Pfizer Inc. to provide access to its proprietary POZ polymer technology. This technology may be used in lipid nanoparticle (LNP) formulations for RNA-based therapeutics. The agreement marks a significant milestone for Serina, indicating potential research and development advancements for Pfizer using the POZ polymer technology.
November 17, 2023 | 1:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Pfizer Inc. has licensed Serina Therapeutics' POZ polymer technology for potential use in RNA-based therapeutic delivery systems, which could enhance Pfizer's research and development capabilities.
The license agreement with Serina Therapeutics provides Pfizer with additional technology that could be significant in the development of RNA-based therapeutics. This could lead to positive investor sentiment in the short term, as it demonstrates Pfizer's commitment to expanding its research capabilities and potentially bringing new products to market.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 80